Related references
Note: Only part of the references are listed.The CXCL12/CXCR4/ACKR3 Axis in the Tumor Microenvironment: Signaling, Crosstalk, and Therapeutic Targeting
Martine J. Smit et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021 (2021)
CCR7 as a therapeutic target in Cancer
Anwar Salem et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)
Design and Characterization of an Intracellular Covalent Ligand for CC Chemokine Receptor 2
Natalia V. Ortiz Zacarias et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
The immunosuppressive and pro-tumor functions of CCL18 at the tumor microenvironment
Ana Patricia Cardoso et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2021)
Chemokines and the immune response to cancer
Aleksandra J. Ozga et al.
IMMUNITY (2021)
Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy
Xuanmao Jiao et al.
BREAST CANCER RESEARCH (2021)
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
Marcus Noel et al.
INVESTIGATIONAL NEW DRUGS (2020)
Optimization of Anti-CXCL10 Nanobody Expression Using Response Surface Methodology and Evaluation of its Anti-metastatic Effect on Breast Cancer cells
Tahereh Sadeghian-Rizi et al.
INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS (2020)
Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018
Yesim A. Tahirovic et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2020)
Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth
Claudio Festuccia et al.
CELLS (2020)
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Bruno Bockorny et al.
NATURE MEDICINE (2020)
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma
Eileen M. O'Reilly et al.
EUROPEAN JOURNAL OF CANCER (2020)
Structural basis of CXC chemokine receptor 2 activation and signalling
Kaiwen Liu et al.
NATURE (2020)
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
Lori J. Goldstein et al.
BREAST CANCER RESEARCH (2020)
Discovery of CCL18 antagonist blocking breast cancer metastasis
Yujie Liu et al.
CLINICAL & EXPERIMENTAL METASTASIS (2019)
Remodeling of the Tumor Microenvironment by a Chemokine/Anti-PD-L1 Nanobody Fusion Protein
Tao Fang et al.
MOLECULAR PHARMACEUTICS (2019)
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology
Xuanmao Jiao et al.
CANCER RESEARCH (2019)
Leukocyte Adhesion: Reconceptualizing Chemokine Presentation by Glycosaminoglycans
Gerard J. Graham et al.
TRENDS IN IMMUNOLOGY (2019)
CCR5 status and metastatic progression in colorectal cancer
Meggy Suarez-Carmona et al.
ONCOIMMUNOLOGY (2019)
Structural Basis for Allosteric Ligand Recognition in the Human CC Chemokine Receptor 7
Kathrin Jaeger et al.
CELL (2019)
GENESIS: Phase III trial evaluating BL-8040+G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma
Zachary D. Crees et al.
FUTURE ONCOLOGY (2019)
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
Marijo Bilusic et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Chemokines and Chemokine Receptors: Orchestrating Tumor Metastasization
Elisabetta Marcuzzi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Synthesis and Pharmacological Evaluation of Triazolopyrimidinone Derivatives as Noncompetitive, Intracellular Antagonists for CC Chemokine Receptors 2 and 5
Natalia V. Ortiz Zacarias et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
Anna E. Vilgelm et al.
FRONTIERS IN IMMUNOLOGY (2019)
Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth
Makito Miyake et al.
THERANOSTICS (2019)
Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer
Daniel O. Villarreal et al.
CANCER RESEARCH (2018)
A guide to chemokines and their receptors
Catherine E. Hughes et al.
FEBS JOURNAL (2018)
Cationic Polymeric Nanoparticle Delivering CCR2 siRNA to Inflammatory Monocytes for Tumor Microenvironment Modification and Cancer Therapy
Song Shen et al.
MOLECULAR PHARMACEUTICS (2018)
Intracellular Receptor Modulation: Novel Approach to Target GPCRs
Natalia V. Ortiz Zacarias et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis
Alessandro Angelini et al.
NATURE COMMUNICATIONS (2018)
92R Monoclonal Antibody Inhibits Human CCR9+ Leukemia Cells Growth in NSG Mice Xenografts
Beatriz Somovilla-Crespo et al.
FRONTIERS IN IMMUNOLOGY (2018)
X4P-001, an orally bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma
Robert H. Andtbacka et al.
CANCER RESEARCH (2018)
Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2
Natalia V. Ortiz Zacarias et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Prajwal Boddu et al.
FRONTIERS IN ONCOLOGY (2018)
Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions
Vladimir Bobkov et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Biased antagonism of CXCR4 avoids antagonist tolerance
Ben Hitchinson et al.
SCIENCE SIGNALING (2018)
Antibody Neutralization of CXCL10 in Vivo Is Dependent on Binding to Free and Not Endothelial-bound Chemokine IMPLICATIONS FOR THE DESIGN OF A NEW GENERATION OF ANTI-CHEMOKINE THERAPEUTIC ANTIBODIES
Pauline Bonvin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer
Ravi Salgia et al.
LUNG CANCER (2017)
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results
Eileen M. O'Reilly et al.
ONCOLOGIST (2017)
Development of novel Promiscuous anti-chemokine Peptibodies for Treating autoimmunity and inflammation
Michal Abraham et al.
FRONTIERS IN IMMUNOLOGY (2017)
Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages
Kelly Kersten et al.
ONCOIMMUNOLOGY (2017)
Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer
Anne F. Schott et al.
CLINICAL CANCER RESEARCH (2017)
Glycosaminoglycan Interactions with Chemokines Add Complexity to a Complex System
Amanda E. I. Proudfoot et al.
PHARMACEUTICALS (2017)
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nisha Nagarsheth et al.
NATURE REVIEWS IMMUNOLOGY (2017)
AZD8797 is an allosteric non-competitive modulator of the human CX3CR1 receptor
Linda Cederblad et al.
BIOCHEMICAL JOURNAL (2016)
Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients
Niels Halama et al.
CANCER CELL (2016)
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Timothy M. Nywening et al.
LANCET ONCOLOGY (2016)
Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells
Fei Shen et al.
MOLECULAR CANCER RESEARCH (2016)
Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists
Yi Zheng et al.
NATURE (2016)
Intracellular allosteric antagonism of the CCR9 receptor
Christine Oswald et al.
NATURE (2016)
A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)
John D. Hainsworth et al.
TARGETED ONCOLOGY (2016)
Targeting of CCL2-CCR2-Glycosaminoglycan Axis Using a CCL2 Decoy Protein Attenuates Metastasis through Inhibition of Tumor Cell Seeding
Marko Roblek et al.
NEOPLASIA (2016)
Covalent Molecular Probes for Class A G Protein-Coupled Receptors: Advances and Applications
Dietmar Weichert et al.
ACS CHEMICAL BIOLOGY (2015)
Targeted delivery of CXCR4-siRNA by scFv for HER2+ breast cancer therapy
Kuo Jiang et al.
BIOMATERIALS (2015)
When structure-affinity relationships meet structure-kinetics relationships: 3-((Inden-1-yl)amino)-1-isopropyl-cyclopentane-1-carboxamides as CCR2 antagonists
Maris Vilums et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Glycosaminoglycan silencing by engineered CXCL12 variants
Martha Gschwandtner et al.
FEBS LETTERS (2015)
Identification of Protein-Ligand Binding Sites by the Level-Set Variational Implicit-Solvent Approach
Zuojun Guo et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2015)
CCR9-mediated signaling through β-catenin and identification of a novel CCR9 antagonist
Sangjun Lee et al.
MOLECULAR ONCOLOGY (2015)
Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges
Maria Vela et al.
FRONTIERS IN IMMUNOLOGY (2015)
Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts
Sonia Chamorro et al.
MABS (2014)
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
Laura Bonapace et al.
NATURE (2014)
GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics
Azra Mujic-Delic et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
Shahneen K. Sandhu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
Kenneth J. Pienta et al.
INVESTIGATIONAL NEW DRUGS (2013)
Neutralizing Nanobodies Targeting Diverse Chemokines Effectively Inhibit Chemokine Function
Christophe Blanchetot et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Llama-derived Single Variable Domains (Nanobodies) Directed against Chemokine Receptor CXCR7 Reduce Head and Neck Cancer Cell Growth in Vivo
David Maussang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Structure-Kinetic Relationships-An Overlooked Parameter in Hit-to-Lead Optimization: A Case of Cyclopentylamines as Chemokine Receptor 2 Antagonists
Maris Vilums et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia
Katie O'Callaghan et al.
BLOOD (2012)
Direct Interaction between an Allosteric Agonist Pepducin and the Chemokine Receptor CXCR4
Jay M. Janz et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2011)
M402, a Novel Heparan Sulfate Mimetic, Targets Multiple Pathways Implicated in Tumor Progression and Metastasis
He Zhou et al.
PLOS ONE (2011)
Identification of a Metalloprotease-Chemokine Signaling System in the Ovarian Cancer Microenvironment: Implications for Antiangiogenic Therapy
Anika Agarwal et al.
CANCER RESEARCH (2010)
Blockade of CCL1 Inhibits T Regulatory Cell Suppressive Function Enhancing Tumor Immunity without Affecting T Effector Responses
Dominique B. Hoelzinger et al.
JOURNAL OF IMMUNOLOGY (2010)
CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells
Sven Jahnichen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Promiscuous drugs as therapeutics for chemokine receptors
Richard Horuk
EXPERT REVIEWS IN MOLECULAR MEDICINE (2009)
Glycosaminoglycan mimetics inhibit SDF-1/CXCL12-mediated migration and invasion of human hepatoma cells
Veronique Friand et al.
GLYCOBIOLOGY (2009)
An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5
Glen Andrews et al.
MOLECULAR PHARMACOLOGY (2008)
Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells
Angela Sutton et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Interleukin-8/CXCL8 is a growth factor for human lung cancer cells
YM Zhu et al.
BRITISH JOURNAL OF CANCER (2004)
LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors
JL Li et al.
JOURNAL OF IMMUNOTHERAPY (2003)
Share Paper
